Kilroy Realty’s stock dropped significantly over the last five years but has recently started to jump back up. The company struggled as many people stopped working in offices, leaving many of their buildings empty. Now, the business is trying to recover by turning some of its properties into labs for science companies to attract new renters.
Sign up free to unlock current fair value, 5 year price projections, and our final verdict.
What does it do?
Kilroy Realty is a mature real estate business that earns money by owning, developing, and leasing high-quality office and laboratory space to tech and life science companies. As a Real Estate Investment Trust (REIT), it buys or builds properties in concentrated West Coast clusters and signs long-term contracts with tenants who pay monthly rent and a share of operating costs. Its revenue flows directly from these lease agreements, which typically last several years and include annual rent increases. Customers keep paying because Kilroy’s buildings are in "trophy" locations with modern amenities that help companies attract top talent.
Where does revenue come from?
The vast majority of Kilroy’s revenue comes from base rent and expense reimbursements from its portfolio of office and life science buildings. It manages over 13 million square feet of space across four main regions: San Francisco, Los Angeles, San Diego, and Seattle. While traditional office space is still the largest segment, the company is actively shifting its mix toward life science laboratories to capture more stable demand from the biotech industry.
Revenue Breakdown
Who are its customers?
Kilroy Realty serves a concentrated group of large technology firms and growing life science companies that require specialized, premium workspaces. Its top tenants often include names like Adobe, Salesforce, and pharmaceutical giants, though its total portfolio occupancy ended 2025 at 81.6%. The company signed a record volume of new leases in the fourth quarter of 2025, but it is still working to fill the 18.4% of its space that remains vacant. It tracks its success through the "leased-to-economic occupancy" spread, which represents the rent it has signed but has not yet started collecting.
What gives it staying power?
Kilroy’s staying power comes from owning some of the most technologically advanced and environmentally sustainable buildings in land-constrained coastal markets. These "Class A" properties are difficult for competitors to build from scratch because of high costs and strict local zoning. However, this advantage is currently under pressure as remote work reduces the overall need for office space.
Where is it headed?
Kilroy is making a major strategic bet on the life science sector by acquiring and developing lab-ready buildings in San Diego’s Torrey Pines cluster. Management recently bought the Nautilus campus for $192 million to expand its footprint in one of the few markets where tenant demand remains strong. If this shift works, Kilroy will become less dependent on the volatile tech office market and more tied to the steady growth of biotech research.
The most important trend is that Kilroy is seeing a divergence between its steady revenue and a sharp decline in its actual earnings power. While annual revenue held steady at $1.11 billion in 2025, GAAP earnings are expected to fall by more than 80% next year as interest costs and empty buildings take their toll.
The quality of cash generation is currently under pressure because Kilroy must spend heavily on building improvements and tenant incentives to fill its empty spaces. Free cash flow turned negative in 2025, hitting minus $120 million, which reveals that the company is spending more on maintaining and developing its properties than it is bringing in from rent.
The balance sheet is managed with a moderate amount of debt, carrying a debt-to-equity ratio of 0.90, which provides some resilience but limits aggressive new spending. Kilroy is sitting on significant assets, but its ability to borrow more is capped by the declining value of office properties and higher market interest rates.
Kilroy is a business in a difficult transition where a high-quality property portfolio is being weighed down by a weak office market and rising development costs.
Leasing volume reached a six-year high in the fourth quarter of 2025, showing that there is still demand for premium space at the right price. This surge in activity suggests that while the office market is tough, Kilroy’s specific buildings are still able to win over tenants from lower-quality competitors.
Occupancy has fallen to 81.6%, a level that makes it difficult for the company to cover its fixed costs and dividends without depleting its cash reserves. If occupancy does not begin a steady climb back toward 90%, Kilroy may be forced to sell assets at a loss or cut its spending on new projects.
The West Coast office and life science market is a multibillion-dollar industry currently facing its most severe downturn in decades due to the rise of remote work. The traditional office market is a mature industry growing at less than 2% annually, with pricing power shifting heavily toward tenants. While the life science niche remains more resilient, the overall sector is defined by high barriers to entry due to land scarcity and zoning laws. Kilroy stands as a high-end niche player, but its concentration in tech-heavy cities like San Francisco makes it vulnerable to the specific hiring freezes and cost-cutting trends currently hitting that industry.
The competitive dynamic for premier office space has become a "flight to quality," where only the newest and best buildings can attract tenants. While the overall market is oversupplied, barriers to building new "trophy" assets are extremely high. This creates a bifurcated market where owners of older buildings are losing everything to owners of modern, sustainable space.
Alexandria Real Estate is the most dangerous threat because it dominates the life science sector that Kilroy is trying to grow into. Boston Properties also competes fiercely for the same large tech tenants in San Francisco and Seattle, often with more diverse geographic footprints that lower their risk. Kilroy is being squeezed by rivals who have either more specialized lab expertise or broader national diversification.
Kilroy is currently losing ground as its occupancy rate remains significantly below its historical levels and its peer group average. The company's 81.6% occupancy rate is a clear signal that it is struggling to defend its market share in a shrinking pool of tenants.
Kilroy’s narrow moat comes from its "intangible assets," specifically its portfolio of highly specialized buildings in prime West Coast locations that are nearly impossible to replicate. These properties are designed for the specific needs of tech and biotech firms, creating a form of switching cost because moving an entire lab or a high-tech headquarters is prohibitively expensive. However, this moat only works when there is a line of tenants waiting to get in.
The numbers tell a story of a moat that is failing to protect profits, as the company’s 2.8% ROIC is well below its cost of capital. High-quality assets should produce higher returns, but the current 18.4% vacancy rate suggests that Kilroy’s "trophy" buildings are being treated more like commodities by cost-conscious tenants. The lack of pricing power is visible in the flat revenue and declining earnings.
The forward verdict is that Kilroy’s moat is eroding as the structural shift to remote work permanently reduces the value of even the best office buildings. The single most important signal is the continued struggle to push occupancy back toward 90% without offering massive rent discounts.
FFO beat in Q4 2025 but occupancy remains low at 81.6% after repeated misses.
Sold $755M in assets to fund $192M Torrey Pines life science acquisition.
CEO took office in 2024; insider stake is growing but still relatively small.
Capital Allocation Track Record
Angela Aman is a proven real estate executive who was brought in to lead a difficult turnaround, and her strategy of "capital recycling" shows a disciplined focus on long-term survival. She has successfully sold nearly $800 million of older properties to fund a pivot into life science labs, which is a smarter bet than doubling down on traditional office space. However, her caliber is still being tested by a market that is moving against her, as the company has struggled to fill its vacant buildings fast enough to stop the decline in earnings.
The primary governance risk is that the company’s future depends entirely on management’s ability to execute this high-stakes pivot without a deep bench of life science expertise. While the board is independent, the strategy is a "person-key" bet on Aman’s vision for a smaller, more specialized Kilroy. If she were to leave before the life science projects are finished and leased, the company would be left with a half-completed portfolio and a massive amount of debt in a sector that few other buyers want to touch.
Clearthesis wrote this report from 39 sources, including SEC filings, industry research, and recent news.
© 2026 Clearthesis.ai · Report generated on July 1, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning neutral because Kilroy's high office vacancy rate creates uncertainty about whether life science growth can save the bottom line. While the firm is pivoting to labs, an 18.4% vacancy rate in its portfolio forces a drop in expected 2026 profits that keeps investors cautious.
Optimists argue that the company is a unique way to gain high-yield exposure to the artificial intelligence boom in Silicon Valley. They believe that as AI companies expand, the demand for Kilroy's premier West Coast lab space will ultimately allow the firm to grow cash flow despite the broader slump in traditional office buildings.